PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Files An 8-K Regulation FD Disclosure

PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure.

On March 27, 2017, Paratek Pharmaceuticals, Inc. and Allergan plc
issued a joint press release announcing top-line data from
Allergan plcs Phase 3 clinical trials of sarecycline for the
treatment of acne. A copy of this press release is attached
hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K is being
furnished to Item 7.01 of Form 8-K and shall not be deemed to be
filed for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject
to the liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release dated March 27, 2017


About PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company’s sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company’s other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Recent Trading Information

PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) closed its last trading session up +0.10 at 15.85 with 407,266 shares trading hands.

An ad to help with our costs